Anchiano Therapeutics Appoints Efrat Makov to its Board of Directors
Former CFO of Alvarion brings decades of experience to Board
CAMBRIDGE, Mass., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of Ms. Efrat Makov to its Board of Directors.
“We warmly welcome Efrat to our Board of Directors,” said Frank Haluska, M.D., Ph.D, President and Chief Executive Officer of Anchiano Therapeutics. “She will be a tremendous asset to our Board as she brings to Anchiano deep financial experience as the former chief financial officer of publicly-traded companies in the US and Israel, as well as her positions as a Director in publicly traded-health care companies in Israel. Her experience, insight, and record of accomplishment and success will prove invaluable as Anchiano progresses to the next stage in its evolution.”
Ms. Makov noted, “I am pleased to join this dynamic Board and look forward to working with Anchiano’s management and helping the company meet the exciting opportunities that lie ahead.”
About Efrat Makov
Ms. Efrat Makov joins the Board after having served as the Chief Financial Officer of Alvarion Ltd. Prior to Alvarion, Ms. Makov served as the Chief Financial Officer of Aladdin Knowledge Systems Ltd. where she was responsible for the finance, operations, information systems and human resources functions. She served as Vice President of Finance at Check Point Software Technologies Ltd. and as Director of Finance for NUR Macroprinters Ltd., after having spent seven years in public accounting with Arthur Andersen in various senior financial positions in its New York, London and Tel Aviv offices. She serves as a Director on the Board of BioLight Life Sciences Ltd. and its subsidiaries. She is an Israel and U.S. Certified Public Accountant. Ms. Makov holds a B.A. in Accounting and Economics from Tel Aviv University.
About Anchiano Therapeutics
Anchiano Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, with offices in Cambridge, MA, and Jerusalem, Israel. The Company’s most advanced product candidate, inodiftagene vixteplasmid (BC-819), is in development as a treatment for non-muscle invasive bladder cancer. For additional information on inodiftagene vixteplasmid or the Codex Trial please go to
Forward Looking Statements
This press release contains “forward-looking statements” that are subject to risks and uncertainties. These forward-looking statements include information about possible or assumed future results of clinical trials, the anticipated effects of receiving Fast Track designation, the anticipated timeframe for conducting additional clinical trials and making regulatory submissions, and other strategic and business plans and objectives. These forward-looking statements are based on information Anchiano Therapeutics has when those statements are made or its management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to: the success of the approach to discover and develop prospective therapeutic products, which is new and may never lead to marketable products; a lack of history of commercial sales; a dependence on the success of inodiftagene, the development of which will require significant additional clinical testing before regulatory approval can be sought and commercial sales launched; a need to raise substantial additional funds to complete R&D activities; an ability to overcome scientific or technological difficulties that may be encountered and that may impede R&D activities; and an ability to obtain and maintain intellectual property protection for product candidates, including pursuant to licensed patents.
Company Contact:
Frank Haluska, M.D., Ph.D.
President and Chief Executive Officer
Investor Contact:
Ashley R. Robinson
Managing Director
LifeSci Advisors, LLC
617-535-7742
